| Registry | NCT07628556 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 74799 (Actual) |
| Sponsor | University of Pecs (Other) |
| Conditions | Cancer |
| Interventions | Metformin, sulphonylurea, DPP-4 inhibitor, GLP-1 Receptor Agonists, SGLT-2 inhibitor, insulin, MET + SU, MET + DPP-4 inhibitor, MET + GLP-1RA, MET + SGLT2i, MET + INS (Drug) |
| Dates | start 2025-03-15, primary completion 2025-12-30, completion 2025-12-30, first posted 2026-06-05, last updated 2026-06-05 |
| Locations | 1 site in Hungary |
Related Papers Related Patents Related Grants Related Experts
All trials for Cancer All trials of Metformin All trials of sulphonylurea
A retrospective analysis was conducted based on data of the National Health Insurance Fund in Hungary. Overall cancer risk and site-specific cancer risks were analysed in a target trial emulation design when comparing all available antidiabetic therapies to MET and monotherapies and primary combination therapies against each other. The model used in the analysis was corrected for age, gender, co-morbidities, selected cardiovascular medications and inpatient and outpatient visits.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Type 2 diabetes mellitus | Drug: Metformin; Drug: sulphonylurea; Drug: DPP-4 inhibitor; Drug: GLP-1 Receptor Agonists; Drug: SGLT-2 inhibitor; Drug: insulin; Drug: MET + SU; Drug: MET + DPP-4 inhibitor; Drug: MET + GLP-1RA; Drug: MET + SGLT2i; Drug: MET + INS |
Sex: All, ages: 19 Years to any
Inclusion Criteria: * Type 2 diabetes mellitus * Antidiabetic medication initiators Exclusion Criteria: * Antidiabetic prescription in the previous 5 years * Recent pancreatectomy (previous or subsequent 90 days after inclusion)
| Facility | City | Country | Status |
|---|---|---|---|
| Pécs | Pécs | Hungary |